Invirsa
4 known investors
Invirsa is a clinical-stage biopharmaceutical company developing DNA damage response therapeutics, with lead compound INV-102 in development for ocular conditions including sulfur mustard gas injury and diabetic dry eye disease.
BiotechDigital HealthMedical Devices
Investors · 4
In the news
- Invirsa, Inc. Raises $15.2M to Advance INV-102 Clinical Trialsleadsontrees.com · 2025
- Invirsa raises $18M for diabetic dry eye treatment trials - Columbus Business Firstbizjournals.com · 2025
- Invirsa secures $7.7 million in funding to advance ocular candidateglance.eyesoneyecare.com · 2023
- CincyTech leads Invirsa's $7.7M Series B to fuel series of Phase 2 studies - Cincinnati Business Courierbizjournals.com · 2023
- Invirsa Secures $520K in Seed Funding - FinSMEsfinsmes.com · 2017
- Invirsa Completes $7.7M Series B Financingstreetinsider.com